Earnings per share for the last twelve months: XBiotech Inc (XBIT)
The targeted robotization of XBiotech Inc. (XBIT) laboratories may seem modest, yet the fundamental TTM net income per share clearly demonstrates efficiency dynamics, with the indicator standing at -1.49. The expansion of the True Human platform to capture market share resolves any doubts, while the use of natural genes enables the company to establish premium pricing for safe cancer therapy methods.
XBiotech Inc - analytical breakdowns and key metrics (XBIT)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- net income and valuation multiples indicators:
XBIT - Company Net Income|Projected Future Earnings XBiotech Inc.|XBIT - Price to Earnings Ratio|Forward P/E Multiple XBiotech USA|XBIT - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio XBiotech Inc.|XBIT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) XBiotech|XBIT - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months xbiotech.com|XBIT - Earnings per share growth this year|Earnings growth forecast for next year XBiotech Inc.
Fundamental company analysis:XBIT - xbiotech.com
Net income per share over 12 months measures the proportional earnings allocated to each share after all expenses are deducted. For XBiotech Inc. (XBIT), this result depends directly on the commercialization of antibodies and the success of clinical trials. By analyzing the TTM earnings per share metric, an investor can discern the actual financial stability of the business. The trend line allows for an assessment of drawdown risks when purchasing the asset. This metric confirms the quality of the company's capitalization.
Main competitors
ONC: Net earnings per share for the last 12 months|HALO - Net earnings per share (EPS TTM)|Revolution Medicines, Inc. (RVMD) - Earnings per share for the last twelve months|Ascentage Pharma Group International - Earnings per share for the trailing year|CGON (CG Oncology Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma Corp URGN|Net earnings per share for the last 12 months BCAX (Bicara Therapeutics Inc.)|personalis.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) ERAS (Erasca)|Delcath Systems Inc - Earnings per share for the last twelve months|YmAbs - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Aura Corp AURA|candeltx.com (CADL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months accuray.com (ARAY)|Net earnings per share for the last 12 months SLS|ACTU (Actuate Therapeutics Inc.) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) CTOR|HURA - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) TARA (Protara Therapeutics)|FATE - Net earnings per share for the last 12 months|Aadi Bio - Net earnings per share (EPS TTM)|Earnings per share for the trailing year TCRX (TScan Therapeutics)|CSBR (championsoncology.com) - Net earnings per share for the last 12 months|CEL-SCI - Earnings per share for the trailing year|OSTX (OS Therapies Incorporated) - Net earnings per share (EPS TTM)|radiopharmtheranostics.com (RADX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Artiva Biotherapeutics, Inc. (ARTV)|adlainortye.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) VERU (Veru Pharma)|TPST - Net earnings per share for the last 12 months|XLO: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Renovaro Inc. RENB|MURA (muraloncology.com) - Net earnings per share for the last 12 months|Earnings per share for the last 12 months KAPA|OKUR (OnKure Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months GDTC|Net earnings per share (EPS TTM) CRIS|Net earnings per share for the last four quarters apollomicsinc.com|Tharimmune - Net earnings per share for the last 12 months|Earnings per share for the last four quarters ADVB (Advanced Biomed Inc.)|Genprex, Inc - Net earnings per share (EPS TTM)|Calidi Biotherapeutics (CLDI) - Net earnings per share for the last 12 months|SBFM: Net earnings per share (EPS TTM)|Xenetic Biosciences, Inc. (XBIO) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Salarius Pharmaceuticals, Inc.|Earnings per share for the last 12 months PPBT (Purple Biotech Ltd)|Net earnings per share (EPS TTM) AONC|Net earnings per share for the last 12 months BeiGene Ltd BGNE|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics)|elevationoncology.com (ELEV) - Net earnings per one share for the last twelve months|ICAD - Earnings per share for the last twelve months|Earnings per share for the trailing year IKNA (Ikena Oncology, Inc.)|NTBL (Notable Labs Inc.) - Net earnings per share for the last 12 months|Viracta Therapeutics, Inc. - Earnings per share for the trailing year|MOR (MorphoSys AG) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months nayabiosciences.com (NAYA)|Net earnings per share for the last 12 months AAPGV (Ascentage Pharma)
